Top

Langenbeck's Archives of Surgery

Published in:

01-12-2015 | REVIEW ARTICLE

Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES)

Authors: Maurizio Iacobone, Bruno Carnaille, F. Fausto Palazzo, Menno Vriens

Published in: Langenbeck's Archives of Surgery | Issue 8/2015

Abstract

Background

Hereditary hyperparathyroidism has been reported to occur in 5–10 % of cases of primary hyperparathyroidism in the context of multiple endocrine neoplasia (MEN) types 1, 2A and 4; hyperparathyroidism-jaw tumour (HPT-JT); familial isolated hyperparathyroidism (FIHPT); familial hypocalciuric hypercalcaemia (FHH); neonatal severe hyperparathyroidism (NSHPT) and autosomal dominant moderate hyperparathyroidism (ADMH). This paper aims to review the controversies in the main genetic, clinical and pathological features and surgical management of hereditary hyperparathyroidism.

Methods

A peer review literature analysis on hereditary hyperparathyroidism was carried out and analyzed in an evidence-based perspective. Results were discussed at the 2015 Workshop of the European Society of Endocrine Surgeons devoted to hyperparathyroidism due to multiple gland disease.

Results

Literature reports scarcity of prospective randomized studies; thus, a low level of evidence may be achieved.

Conclusions

Hereditary hyperparathyroidism typically presents at an earlier age than the sporadic variants. Gene penetrance and expressivity varies. Parathyroid multiple gland involvement is common, but in some variants, it may occur metachronously often with long disease-free intervals, simulating a single-gland involvement. Bilateral neck exploration with subtotal parathyroidectomy or total parathyroidectomy + autotransplantation should be performed, especially in MEN 1, in order to decrease the persistent and recurrent hyperparathyroidism rates; in some variants (MEN 2A, HPT-JT), limited parathyroidectomy can achieve long-term normocalcemia. In FHH, surgery is contraindicated; in NSHPT, urgent total parathyroidectomy is required. In FIHPT, MEN 4 and ADMH, a tailored case-specific approach is recommended.

Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML (2009) Surgical approach in hereditary hyperparathyroidism. Endocr J 56(7):827–41PubMedCrossRef

Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–9. doi:10.1210/jc.2014-1414 PubMedCrossRef

Udelsman R, Akerström G, Biagini C, Duh QY, Miccoli P, Niederle B, Tonelli F (2014) The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99(10):3595–606. doi:10.1210/jc.2014-2000 PubMedCrossRef

Heinrich S, Schafer M, Rousson V, Clavien PA (2006) Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 243:154–68PubMedCentralPubMedCrossRef

Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, for the GRADE Working Group (2008) Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–6PubMedCentralPubMedCrossRef

Lips CJ, Valk GD, Dreijerink KM, Timmers M, van der Luijt RB, Links T, van Nesselrooij BPM, Vriens MR, Höppener JW, Borel Rinkes IHM (2015) Multiple Endocrine Neoplasia 1. In: Weiss, Retetoff (ed) Genetic Diagnosis on Endocrine Disorders, in press

Dreijerink KM, Goudet P, Burgess JR, Valk GD, International Breast Cancer in MEN1 Study Group (2014) Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med 7 371(6):583–584CrossRef

de Laat JM, Tham E, Pieterman CR, Vriens MR, Dorresteijn JA, Bots ML, Nordenskjöld M, van der Luijt RB, Valk GD (2012) Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors. Eur J Endocrinol 167(2):181–7PubMed

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Endocrine Society. J Clin Endocrinol Metab 97(9):2990–3011PubMedCrossRef

10.

Brandi ML, Gagel RF, Angeli A et al (2001) Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–71PubMedCrossRef

11.

Roijers JF, de Wit MJ, van der Luijt RB, Ploos van Amstel HK, Höppener JW, Lips CJ (2000) Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. Eur J Clin Invest 30:487–92PubMedCrossRef

12.

Prinz RA, Gamvros OI, Sellu D et al (1981) Subtotal parathyroidectomy for primary chief cell hyperplasia of the multiple endocrine neoplasia type 1 syndrome. Ann Surg 193:26–9PubMedCentralPubMedCrossRef

13.

Rizzoli R, Green J 3rd, Marx SJ (1985) Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 78(3):467–74PubMedCrossRef

14.

Malmaeus J, Benson L, Johansson H, Ljunghall S, Rastad J, Akerström G, Oberg K (1986) Parathyroid surgery in the multiple endocrine neoplasia type I syndrome: choice of surgical procedure. World J Surg 10(4):668–72PubMedCrossRef

15.

O’Riordain DS, O’ Brian T, Grant CS et al (1993) Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1 and 2. Surgery 114:1031–9PubMed

16.

Cougard P, Proye C (1994) Hyperparathyroidism and multiple endocrine neoplasia type 1 (MEN-1). Acta Chir Austriaca 26(112):32–5

17.

Hellmann P, Skogseid B, Oberg K et al (1998) Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery 124:993–9CrossRef

18.

Burgess JR, David R, Parameswaran V, Greenaway TM, Shepherd JJ (1998) The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 133(2):126–9PubMedCrossRef

19.

Dotzenrath C, Cupisti K, Goretzki PE et al (2001) Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg 167:173–8PubMedCrossRef

20.

Arnalsteen LC, Alesina PF, Quireux JL et al (2002) Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 132:1119–25PubMedCrossRef

21.

Elaraj DM, Skarulis MC, Libutti SK et al (2003) Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 134:858–65PubMedCrossRef

22.

Langer P, Wild A, Schilling T, Nies C, Rothmund M, Bartsch DK (2004) Multiple endocrine neoplasia type 1. Surgical therapy of primary hyperparathyroidism. Chirurg 75(9):900–6PubMedCrossRef

23.

Lambert LA, Shapiro SE, Lee JE, Perrier ND, Truong M, Wallace MJ, Hoff AO, Gagel RF, Evans DB (2005) Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg 140(4):374–82PubMedCrossRef

24.

Lee CH, Tseng LM, Chen JY, Hsiao HY, Yang AH (2006) Primary hyperparathyroidism in multiple endocrine neoplasia type 1: individualized management with low recurrence rates. Ann Surg Oncol 13(1):103–9PubMedCrossRef

25.

Hubbard JGH, Sebag F, Maweja S et al (2006) Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 141:235–9PubMedCrossRef

26.

Tonelli F, Marcucci T, Fratini G et al (2007) Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 246:1075–82PubMedCrossRef

27.

Norton JA, Venzon DJ, Berna MJ et al (2008) Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 247:501–10PubMedCentralPubMedCrossRef

28.

Salmeron MD, Gonzalez JM, Sancho Insenser J, Goday A, Perez NM, Zambudio AR, Paricio PP, Serra AS (2010) Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World J Surg 34(6):1325–31PubMedCrossRef

29.

Waldmann J, López CL, Langer P, Rothmund M, Bartsch DK (2010) Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg 97(10):1528–34PubMedCrossRef

30.

Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Rinkes IH (2011) The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg 35(9):1993–2005PubMedCrossRef

31.

Versnick M, Popadich A, Sidhu S, Sywak M, Robinson B, Delbridge L (2013) Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism. Surgery 154(1):101–5PubMedCrossRef

32.

Lairmore TC, Govednik CM, Quinn CE, Sigmond BR, Lee CY, Jupiter DC (2014) A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 156(6):1326–34PubMedCrossRef

33.

Stålberg P, Carling T (2009) Familial parathyroid tumors: diagnosis and management. World J Surg 33:2234–43PubMedCrossRef

34.

Twigt BA, Scholten A, Valk GD, Rinkes IH, Vriens MR (2013) Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis 8:50PubMedCentralPubMedCrossRef

35.

VanderWalde LH, Haigh PI (2006) Surgical approach to the patient with familial hyperparathyroidism. Curr Treat Options Oncol 7:326–33PubMedCrossRef

36.

Goudet P, Cougard P, Vergès B et al (2001) Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D’etude des Néoplasies Endocriniennes Multiples study group. World J Surg 25:886–90PubMedCrossRef

37.

Mihai R, Barczynski M, Iacobone M, Sitges-Serra A (2009) Surgical strategy for sporadic primary hyperparathyroidism an evidence-based approach to surgical strategy, patient selection, surgical access, and reoperations. Langenbecks Arch Surg 394(5):785–98PubMedCrossRef

38.

Kraimps JL, Duh QY, Demeure M, Clark OH (1992) Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery 112:1080–6PubMed

39.

Pieterman CR, van Hulsteijn LT, den Heijer M, van der Luijt RB, Bonenkamp JJ, Hermus AR, Borel Rinkes IH, Vriens MR, Valk GD (2012) Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. DutchMEN1 Study Group. Ann Surg 255(6):1171–8PubMedCrossRef

40.

Raue F, Frank-Raue K (2010) Update multiple endocrine neoplasia type 2. Fam Cancer 9(3):449–57PubMedCrossRef

41.

Giusti F, Cavalli L, Cavalli T, Brandi ML (2013) Hereditary hyperparathyroidism syndromes. J Clin Densitom 16(1):69–74PubMedCrossRef

42.

Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, Boneu A, Roger P, Houdent C, Barbier J, Modigliani E (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs á Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20(7):808–12PubMedCrossRef

43.

Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238(4):369–73PubMedCrossRef

44.

Herfarth KK, Bartsch D, Doherty GM, Wells SA Jr, Lairmore TC (1996) Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120(6):966–73PubMedCrossRef

45.

Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee NY, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah MH, Waguespack SG (2015) Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma. The American Thyroid Association Guidelines task force on medullary thyroid carcinoma. Thyroid 25(6):567–610PubMedCrossRef

46.

Borot S, Lapierre V, Carnaille B, Goudet P, Penfornis A (2010) Results of cryopreserved parathyroid autografts: a retrospective multicenter study. Surgery 147(4):529–35PubMedCrossRef

47.

Bradley KJ, Hobbs MR, Buley ID et al (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 257:18–26PubMedCrossRef

48.

Mehta A, Patel D, Rosenberg A, Boufraqech M, Ellis RJ, Nilubol N, Quezado MM, Marx SJ, Simonds WF, Kebebew E (2014) Hyperparathyroidism-jaw tumor syndrome: Results of operative management. Surgery 156:1315–25PubMedCentralPubMedCrossRef

49.

Jackson CE, Norum RA, Boyd SB et al (1990) Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108:1006–12PubMed

50.

Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–80PubMedCrossRef

51.

Porzionato A, Macchi V, Barzon L et al (2006) Immunohistochemical assessment of parafibromin in mouse and human tissues. J Anat 209:817–27. doi:10.1111/j.1469-7580.2006.00657.x PubMedCentralPubMedCrossRef

52.

Masi G, Iacobone M, Sinigaglia A, Mantelli B, Pennelli G, Castagliuolo I, Palù G, Barzon L (2014) Characterization of a new CDC73 missense mutation that impairs parafibromin expression and nucleolar localization. PLoS One 9(5):e97994PubMedCentralPubMedCrossRef

53.

Juhlin C, Larsson C, Yakoleva T et al (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr-Relat Cancer 13:509–23. doi:10.1677/erc.1.01058 PubMedCrossRef

54.

Bradley KJ, Cavaco BM, Bowl MR et al (2006) Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) 64:299–306. doi:10.1111/j.1365-2265.2006.02460.x CrossRef

55.

Masi G, Barzon L, Iacobone M et al (2008) Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr-Relat Cancer 15:1115–26. doi:10.1677/ ERC-08-0066 PubMedCrossRef

56.

Mizusawa N, Uchino S, Iwata T et al (2006) Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 65:9–16CrossRef

57.

Gimm O, Lorenz K, Nguyen Thanh P et al (2006) Das Familiäre Nebenschilddrüsenkarzinom. Indikation zur prophylaktischen Parathyreoidektomie? Chirurg 77:15–24. doi:10.1007/s00104- 005-1110-2 PubMedCrossRef

58.

Pichardo-Lowden AR, Manni A, Saunders BD, Baker MJ (2011) Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. Endocr Pract 17:602–9PubMedCrossRef

59.

Iacobone M, Lumachi F, Favia G (2004) Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 88:223–8. doi:10.1002/jso.20152 PubMedCrossRef

60.

Kelly TG, Shattuck TM, Reyes-Mugica M et al (2006) Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 21:1666–71PubMedCrossRef

61.

Shattuck TM, Valimaki S, Obara T et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–9. doi:10.1056/NEJMoa031237 PubMedCrossRef

62.

Howell VM, Haven CJ, Kahnoski K et al (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657–63. doi:10.1136/jmg.40.9.657 PubMedCentralPubMedCrossRef

63.

Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89:96–102PubMedCrossRef

64.

Cetani F, Pardi E, Borsari SL et al (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89:5583–91. doi:10.1210/jc.2004-0294 PubMedCrossRef

65.

Villablanca A, Calender A, Forsberg L et al (2004) Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41:e32PubMedCentralPubMedCrossRef

66.

Cavaco BM, Guerra L, Bradley KJ et al (2004) Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab 89:1747–52. doi:10.1210/jc.2003-031016 PubMedCrossRef

67.

Howell VM, Zori RT, Stalker HJ et al (2004) A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones. J Pediatr 145(4):567PubMedCrossRef

68.

Moon SD, Park JH, Kim EM et al (2005) A Novel IVS2-1G > A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 90:878–83PubMedCrossRef

69.

Aldred MJ, Talacko AA, Savarirayan R et al (2006) Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:212–8PubMedCrossRef

70.

Guarnieri V, Scillitani A, Muscarella LA et al (2006) Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab 91:2827–32PubMedCrossRef

71.

Yamashita Y, Akiyama T, Mizusawa N, Yoshimoto K, Goto M (2007) A case of hyperparathyroidism-jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone. Int J Oral Maxillofac Surg 36:365–9PubMedCrossRef

72.

Cetani F, Pardi E, Ambrogini E et al (2007) Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr Relat Cancer 14:493–9PubMedCrossRef

73.

Cetani F, Ambrogini E, Viacava P et al (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156:547–54PubMedCrossRef

74.

Raue F, Haag C, Frank-Raue K (2007) Hyperparathyroidism-jaw tumor syndrome. A hereditary form of primary hyperparathyroidism with parathyroid carcinoma. Dtsch Med Wochenschr 132:1459–62PubMedCrossRef

75.

Cetani F, Pardi E, Ambrogini E et al (2008) Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest 31:900–4PubMedCrossRef

76.

Sarquis MS, Silveira LG, Pimenta FJ et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow up in three families with germline HRPT2 mutations. Surgery 143:630–40. doi:10.1016/j.surg.2007.12.012 PubMedCrossRef

77.

Guarnieri V, Bisceglia M, Bonfitto N et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations (letter to the editor). Surgery 144:839–40. doi:10.1016/j.surg.2008.08.008 PubMedCrossRef

78.

Howell VM, Gill A, Clarkson A et al (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94:434–41PubMedCrossRef

79.

Silveira LG, Dias EP, Marinho BC, Gomez RS, De Marco L, Sarquis MS (2008) HRPT2-related familial isolated hyperparathyroidism: could molecular studies direct the surgical approach? Arq Bras Endocrinol Metabol 52:1211–20PubMedCrossRef

80.

Schmidt BP, Bradrick JP, Gabali A (2009) Hyperparathyroidism-jaw tumor syndrome: a case report. J Oral Maxillofac Surg 67(2):423–7. doi:10.1016/j.joms.2008.07.015 PubMedCrossRef

81.

Rekik N, Ben Naceur B, Mnif M et al (2010) Hyperparathyroidism-jaw tumor syndrome: a case report. Ann Endocrinol (Paris) 71:121–6CrossRef

82.

Panicker LM, Zhang JH, Dagur PK, Gastinger MJ, Simonds WF (2010) Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. Endocr Relat Cancer 17:513–24PubMedCentralPubMedCrossRef

83.

Veiguela B, Isidro ML, Jorge S, Ruano B (2010) An uncommon cause of hypercalcemia: synchronous carcinoma of two parathyroids in the context of hyperparathyroidism-jaw tumor syndrome. Endocrinol Nutr 57(8):391–3. doi:10.1016/j.endonu.2010.04.002 PubMedCrossRef

84.

Cavaco BM, Santos R, Felix A et al (2011) Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses. Endocr Pathol 22:44–52PubMedCrossRef

85.

Frank-Raue L-BG, Lorenz A, Rondot S, Haag C, Schulze E, Büchler M, Raue F (2011) Hereditary variants of primary hyperparathyroidism. MEN1, MEN2, HPT-JT, FHH, FIHPT. Dtsch Med Wochenschr 136(38):1889–94. doi:10.1055/s-0031-1286358 PubMedCrossRef

86.

Cascón A, Huarte-Mendicoa CV, Javier Leandro-García L et al (2011) Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. Genes Chromosom Cancer 50(11):922–9. doi:10.1002/gcc.20911 PubMedCrossRef

87.

Siu WK, Law CY, Lam CW et al (2011) Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors. Fam Cancer 10(4):695–9. doi:10.1007/s10689-011-9466-6 PubMedCrossRef

88.

Domingues R, Tomaz RA, Martins C, Nunes C, Bugalho MJ, Cavaco BM (2012) Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism. Clin Endocrinol (Oxf) 76:33–8CrossRef

89.

Guerrouani A, Rzin A, El Khatib K (2013) Hyperparathyroidism-jaw tumour syndrome detected by aggressive generalized osteitis fibrosa cystica. Clin Cases Miner Bone Metab 10(1):65–7. doi:10.11138/ccmbm/2013.10.1.065 PubMedCentralPubMed

90.

Bricaire L, Odou MF, Cardot-Bauters C et al (2013) Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98:E403–8PubMedCrossRef

91.

Kutcher MR, Rigby MH, Bullock M, Trites J, Taylor SM, Hart RD (2013) Hyperparathyroidism-jaw tumor syndrome. Head Neck 35(6):E175–7. doi:10.1002/hed.22918 PubMedCrossRef

92.

Ghemigian A, Ghemigian M, Popescu I et al (2013) Familial isolated primary hyperparathyroidism due to HRPT2 mutation. Hormones (Athens) 12(3):454–60

93.

Abdulla AG, O'Leary EM, Isorena JP, Diaz MF, Yeh MW (2013) Recurrent hyperparathyroidism and a novel nonsense mutation in a patient with hyperparathyriodism-jaw tumor syndrome. Endocr Pract 19(6):e134–7. doi:10.4158/EP13187.CR PubMedCrossRef

94.

Pazienza V, La Torre A, Baorda F et al (2013) Identification and functional characterization of three NoLS (nucleolar localisation signals) mutations of the CDC73 gene. PLoS One 8(12):e82292. doi:10.1371/journal.pone.0082292 PubMedCentralPubMedCrossRef

95.

Kong J, Wang O, Nie M, Shi J, Hu Y, Jiang Y, Li M, Xia W, Meng X, Xing X (2014) Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese. Clin Endocrinol (Oxf) 81(2):222–30. doi:10.1111/cen.12461 CrossRef

96.

Chiofalo MG, Sparaneo A, Chetta M et al (2014) A novel CDC73 gene mutation in an Italian family with hyperparathyroidism-jaw tumour (HPT-JT) syndrome. Cell Oncol (Dordr) 37(4):281–8. doi:10.1007/s13402-014-0187-3 CrossRef

97.

Korpi-Hyövälti E, Cranston T, Ryhänen E, Arola J, Aittomäki K, Sane T, Thakker RV, Schalin-Jäntti C (2014) CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. J Clin Endocrinol Metab 99(9):3044–8. doi:10.1210/jc.2014-1481 PubMedCentralPubMedCrossRef

98.

Sriphrapradang C, Sornmayura P, Chanplakorn N, Trachoo O, Sae-Chew P, Aroonroch R (2014) Fine-needle aspiration cytology of parathyroid carcinoma mimic hürthle cell thyroid neoplasm. Case Rep Endocrinol 2014:680876. doi:10.1155/2014/680876 PubMedCentralPubMed

99.

Iacobone M, Masi G, Barzon L et al (2009) Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 394:817–25PubMedCrossRef

100.

Iacobone M, Barzon L, Porzionato A et al (2007) Parafibromin expression, single-gland involvement and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery 142:984–91. doi:10.1016/j.surg.2007.09.029 PubMedCrossRef

101.

Iacobone M, Barzon L, Porzionato A et al (2009) The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. Surgery 145:250–1. doi:10.1016/j.surg.2008.06.027 PubMedCrossRef

102.

Carling T, Udelsman R (2005) Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 257:27–37PubMedCrossRef

103.

Iacobone M, Ruffolo C, Lumachi F, Favia G (2005) Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 390:385–90. doi:10.1007/s00423-005-0555-6 PubMedCrossRef

104.

Fritz A, Walch A, Piotrowska K, Rosemann M, Schäffer E, Weber K, Timper A, Wildner G, Graw J, Höfler H, Atkinson MJ (2002) Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 62(11):3048–51PubMed

105.

Molatore S, Pellegata NS (2010) The MENX syndrome and p27: relationships with multiple endocrine neoplasia. Prog Brain Res 182:295–320PubMedCrossRef

106.

Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103(42):15558–63PubMedCentralPubMedCrossRef

107.

Thakker RV (2014) Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 386(1-2):2–15PubMedCentralPubMedCrossRef

108.

Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, Degli Uberti EC, Zatelli MC, Pellegata NS (2010) A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 31(11):E1825–35PubMedCentralPubMedCrossRef

109.

Marinoni I, Pellegata NS (2011) p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 93(1):19–28PubMedCrossRef

110.

Tonelli F, Giudici F, Giusti F, Marini F, Cianferotti L, Nesi G, Brandi ML (2014) A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. Eur J Endocrinol 171(2):K7–17PubMedCrossRef

111.

Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA (2007) Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 92(8):3321–5PubMedCrossRef

112.

Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94(5):1826–34. doi:10.1210/jc.2008-2083 PubMedCentralPubMedCrossRef

113.

Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A (2011) Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 96(4):E701–6PubMedCentralPubMedCrossRef

114.

Pellegata NS (2012) MENX and MEN4. Clinics 67(1):13–8PubMedCentralPubMedCrossRef

115.

Lee M, Pellegata N (2013) Multiple endocrine neoplasia type 4. Front Horm Res 41:63–78PubMedCrossRef

116.

Wassif WS, Moniz CF, Friedman E et al (1993) Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77:1485–9PubMed

117.

Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81(1):1–26CrossRef

118.

Giusti F, Cavalli L, Cavalli T, Brandi ML (2013) Hereditary hyperparathyroidism syndromes. J Clin Densitom: Assessment Skelet Health 16(1):69–74CrossRef

119.

Larsson C (2000) Dissecting the genetics of hyperparathyroidism—new clues from an old friend. J Clin Endocrinol Metab 85:1752–4PubMed

120.

Hannan FM, Thakker RV (2013) Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best Pract Res Clin Endocrinol Metab 27(3):359–71PubMedCrossRef

121.

Christensen SE, Nissen PH, Verstergaard P et al (2008) Plasma 25-hydroxyvitmain D, 1,25-dihydroxyvitmain D, and PTH in familial hypocalciuric hypercalcaemia (FHH) and primary hyperparathyroidism (PHPT). Eur J Endocrinol 159(6):719–27PubMedCrossRef

122.

Isaksen T, Nielsen CS, Christensen SE et al (2011) Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif Tissue Int 89:285–94PubMedCrossRef

123.

Calcium sensing receptor database. http://www.casrdb.mcgill.ca. Accessed 24 April 2015

124.

Egbuna OI, Brown EM (2008) Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 22:129–48PubMedCentralPubMedCrossRef

125.

Varghese J, Rich T, Jimenez C (2011) Benign familial hypocalciuric hypercalcaemia. Endocr Pract 17(1):13–7PubMedCrossRef

126.

Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L (2008) Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 69(5):713–20. doi:10.1111/j.1365-2265.2008.03259.x CrossRef

127.

Law WM Jr, Carney JA, Heath H 3rd (1984) Parathyroid glands in familial benign hypercalcemia (familial hypocalciuric hypercalcaemia). Am J Med 76:1021–6PubMedCrossRef

128.

Thorgeirsson U, Costa J, Marx SJ (1981) The parathyroid glands in familial hypocalciuric hypercalcemia. Hum Pathol 12:229–37PubMedCrossRef

129.

Lietman SA, Tenenbaum-Rakover Y, Jap TS et al (2009) A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia. J Clin Endocrinol Metab 94:4372–9PubMedCentralPubMedCrossRef

130.

Gunn IR, Gaffney D (2004) Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem 41:441–58PubMedCrossRef

131.

Pearce S, Steinmann B (1999) Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clin Endocrinol (Oxf) 50:691–3CrossRef

132.

Waller S, Kurzawinski T, Spitz L et al (2004) Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr 163:589–94PubMedCrossRef

133.

Pollak MR, Chou YH, Marx SJ et al (1994) Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 93:1108–12PubMedCentralPubMedCrossRef

134.

Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E (2012) Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics 129:e812–6PubMedCrossRef

135.

Carling T, Szabo E, Bai M et al (2000) Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85(5):2042–7PubMed

136.

Akerström G (2009) Symposium on evidence-based endocrine surgery (hyperparathyroidism). World J Surg 33:2219–23PubMedCrossRef

137.

Starker LF, Akerström T, Long WD, Delgado-Verdugo A, Donovan P, Udelsman R, Lifton RP, Carling T (2012) Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer 3:44–51PubMedCrossRef

138.

Skandarajah A, Barlier A, Morlet-Barlat N, Sebag F, Enjalbert A, Conte-Devolx B, Henry JF (2010) Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg 34(6):1294–8. doi:10.1007/s00268-009-0388-5 PubMedCrossRef

139.

Costa-Guda J, Soong CP, Parekh VI, Agarwal SK, Arnold A (2013) Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in in sporadic parathyroid adenomas. Horm Cancer 4:301–7PubMedCrossRef

140.

Falchetti A, Marini F, Giusti F et al (2009) DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. J Intern Med 266:69PubMedCrossRef

141.

Marx SJ, Simonds WF, Agarwal SK et al (2002) Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 17(2):N37–43PubMed

Title: Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES)
Authors: Maurizio Iacobone
Bruno Carnaille
F. Fausto Palazzo
Menno Vriens
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Langenbeck's Archives of Surgery / Issue 8/2015
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-015-1342-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2015

Totally laparoscopic gastrectomy for gastric cancer after endoscopic submucosal dissection: a propensity score matching analysis

Sporadic multiple parathyroid gland disease—a consensus report of the European Society of Endocrine Surgeons (ESES)

Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature

Transanal total mesorectal excision for rectal cancer: a single center experience and systematic review of the literature

Multigland primary hyperparathyroidism—frequently considered, seldom encountered

Automated low flow pump system for the treatment of refractory ascites: a single-center experience